Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.
Also called NCT01584557
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 250 participants
- Sponsor
- Cardiovascular Clinical Sciences Inc
- Registry
-
NCT01584557
-
- Other papers using this trial's data
- Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01584557. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2016-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management
- Acronym
- Secret of CHF
- Condition
- Heart Failure
- Intervention (Drug)
- Tolvaptan or Samsca
- Intervention (Drug)
- placebo or sugar pill
- Lead sponsor
- Cardiovascular Clinical Sciences Inc
Record details
- Record id
cardio:ct-nct01584557- Content hash
c1c88b1c5ab39ebe68626c39ab6ddff76d2caa26a51e9023049d1534fc10c1cc